David Badawi Sells 3,051 Shares of Sight Sciences (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,051 shares of Sight Sciences stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $7.82, for a total transaction of $23,858.82. Following the transaction, the chief technology officer directly owned 1,920,804 shares in the company, valued at approximately $15,020,687.28. The trade was a 0.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

David Badawi also recently made the following trade(s):

• On Tuesday, January 6th, David Badawi sold 3,695 shares of Sight Sciences stock. The stock was sold at an average price of $7.48, for a total value of $27,638.60.
• On Friday, January 2nd, David Badawi sold 2,914 shares of Sight Sciences stock. The shares were sold at an average price of $7.43, for a total value of $21,651.02.

Sight Sciences Trading Down 0.4%

Shares of NASDAQ:SGHT opened at $7.44 on Thursday. The company has a market capitalization of $393.35 million, a PE ratio of -8.27 and a beta of 2.42. The company has a current ratio of 9.60, a quick ratio of 8.93 and a debt-to-equity ratio of 0.62. Sight Sciences, Inc. has a 12-month low of $2.03 and a 12-month high of $9.24. The business’s fifty day simple moving average is $7.57 and its 200-day simple moving average is $5.15.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) earnings per share for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The company had revenue of $12.54 million for the quarter. As a group, equities research analysts predict that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Key Headlines Impacting Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight, which can attract buying from institutions and retail investors and support near-term positive sentiment. Read More.
• Neutral Sentiment: Key insiders still hold large stakes (CEO Paul Badawi ~5.9M shares; CTO David Badawi ~1.9M shares), which suggests ongoing long-term alignment despite recent sales and may limit fears of full insider exit. Read More.
• Negative Sentiment: Multiple executives (CEO, CTO, CFO, EVP and other insiders) disclosed sales between Jan. 2–6 totaling roughly $0.48M in proceeds. The clustered timing and size of the trades — even though each is a small percentage of holdings — can create short-term downward pressure or signal near‑term liquidity needs. Read More.

Institutional Investors Weigh In On Sight Sciences

A number of institutional investors and hedge funds have recently modified their holdings of SGHT. BNP Paribas Financial Markets boosted its position in Sight Sciences by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock valued at $26,000 after buying an additional 3,785 shares during the last quarter. CWM LLC lifted its stake in Sight Sciences by 70.2% during the 2nd quarter. CWM LLC now owns 7,607 shares of the company’s stock valued at $31,000 after acquiring an additional 3,137 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Sight Sciences by 32.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after acquiring an additional 2,875 shares during the last quarter. Bank of Montreal Can purchased a new stake in shares of Sight Sciences in the 2nd quarter valued at $49,000. Finally, Vanguard Personalized Indexing Management LLC increased its stake in shares of Sight Sciences by 38.9% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company’s stock worth $66,000 after acquiring an additional 4,453 shares during the period. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Sight Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Morgan Stanley raised their target price on shares of Sight Sciences from $6.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Piper Sandler set a $9.00 price target on Sight Sciences in a research report on Monday. Raymond James Financial set a $9.00 price objective on shares of Sight Sciences in a report on Monday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research note on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.30.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.